Clinical Trials
9
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
Safety and Efficacy of KPI-121 in Subjects With DED
- Conditions
- Kerato Conjunctivitis Sicca
- Interventions
- Drug: KPI-121 Ophthalmic SuspensionDrug: Vehicle
- First Posted Date
- 2018-08-06
- Last Posted Date
- 2021-04-02
- Lead Sponsor
- Kala Pharmaceuticals, Inc.
- Target Recruit Count
- 901
- Registration Number
- NCT03616899
- Locations
- 🇺🇸
Investigator #133, Birmingham, Alabama, United States
🇺🇸Investigator #278, Dothan, Alabama, United States
🇺🇸Investigator #146, Chandler, Arizona, United States
KPI-121 1% Versus Prednisolone for the Treatment of Inflammation Following Cataract Surgery in Children
- Conditions
- Ocular Inflammation
- Interventions
- Drug: KPI-121 1%
- First Posted Date
- 2018-07-24
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- Kala Pharmaceuticals, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT03596723
- Locations
- 🇺🇸
Byers Eye Institute at Stanford University, Palo Alto, California, United States
🇺🇸Children's Eye Care, PC, Detroit, Michigan, United States
🇺🇸Pediatric Ophthalmology of Erie, Inc., Erie, Pennsylvania, United States
Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease
- Conditions
- Keratoconjunctivitis SiccaDry Eye Syndromes
- Interventions
- Drug: Vehicle of KPI-121 0.25% Ophthalmic SuspensionDrug: KPI-121 0.25% Ophthalmic Suspension
- First Posted Date
- 2016-06-30
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Kala Pharmaceuticals, Inc.
- Target Recruit Count
- 909
- Registration Number
- NCT02819284
- Locations
- 🇺🇸
UAB School of Optometry, Birmingham, Alabama, United States
🇺🇸Arizona Eye Center, Chandler, Arizona, United States
🇺🇸NEA Baptist Clinic, Jonesboro, Arkansas, United States
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
- Conditions
- Keratoconjunctivitis SiccaDry Eye Syndromes
- Interventions
- Drug: KPI-121 0.25% Ophthalmic SuspensionDrug: Vehicle of KPI-121 0.25% Ophthalmic Suspension
- First Posted Date
- 2016-06-24
- Last Posted Date
- 2021-02-03
- Lead Sponsor
- Kala Pharmaceuticals, Inc.
- Target Recruit Count
- 918
- Registration Number
- NCT02813265
- Locations
- 🇺🇸
Cornea and Cataract Consultants of Arizona, Phoenix, Arizona, United States
🇺🇸Schwartz Laser Eye Center, Scottsdale, Arizona, United States
🇺🇸Eyecare Arkansas, P.A., Little Rock, Arkansas, United States
Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain
- Conditions
- Post Surgical Ocular Inflammation and Pain
- Interventions
- Drug: KPI-121 1% Ophthalmic Suspension dosed BIDDrug: Vehicle of KPI-121 Ophthalmic Suspension dosed BID
- First Posted Date
- 2016-06-08
- Last Posted Date
- 2020-12-16
- Lead Sponsor
- Kala Pharmaceuticals, Inc.
- Target Recruit Count
- 520
- Registration Number
- NCT02793817
- Locations
- 🇺🇸
Arizona Eye Center, Chandler, Arizona, United States
🇺🇸Cornea and Cataract Consultants of CA, Phoenix, Arizona, United States
🇺🇸Sall Research Medical Center, Artesia, California, United States
- Prev
- 1
- 2
- Next